Construction of a plasmid vector of fused protein genes driven by human insulin-like growth factor Ⅱ P3 promoter
- Author:
- No author available
- Journal Title:
- NATIONAL MEDICAL JOURNAL OF CHINA
- Issue:
- 2
- DOI:
- 10.3760/j:issn:0376-2491.2006.02.008
- Key Word:
- 胰岛素样生长因子Ⅱ;质粒;癌,肝细胞;胸苷激酶
Abstract： 目的构建人胰岛素样生长因子Ⅱ基因(IGF-Ⅱ)P3启动子驱动的单纯疱疹病毒胸苷激酶(HSV-tk)与增强型绿色荧光蛋白(EGFP)融合基因穿梭质粒,观察其在肝癌细胞株HepG2及宫颈癌细胞株HeLa细胞中的表达及其作用.方法应用基因重组技术,构建IGF-ⅡP3启动子驱动EGFP与HSV-tk融合表达穿梭质粒载体,脂质体转染技术将其转入HepG2及HeLa中,48 h后荧光显微镜下观察荧光表达,逆转录聚合酶链反应(RT-PCR)检测HSV-tk和EGFP的mRNA表达,四甲基偶氮唑蓝实验检测转染融合蛋白载体后给予不同浓度的更昔洛韦对HepG2及HeLa细胞毒作用.结果 酶切鉴定和测序分析证实重组质粒构建成功;转染此穿梭质粒的细胞中仅有HepG2细胞检测到绿色荧光;RT-PCR检测到HSV-tk和EGFP的mRNA仅在HepG2细胞中表达;更昔洛韦(GCV)对转染了携此质粒载体的HepG2细胞有选择性细胞毒作用,1、10、和100μg/ml 3个浓度GCV作用72 h后(实验均重复3次),对转染细胞的抑制率分别为19.8%±1.3%、36.2%±2.0%和48.7%±1.9%,与细胞病毒转染HepG2组(24.1%±1.9%、45.1%±1.7%、69.4%±3.6%)和此质粒转染HeLa细胞组(25.1%±1.6%、49.3%±1.1%、72.2%±2.9%)相比,差异有统计学意义(均P＜0.01).结论 成功构建IGF-ⅡP3启动子驱动携带HSV-HSV-tk与EGFP融合基因穿梭质粒载体,转染后对人肝癌细胞系HepG2有选择性杀伤作用,为进一步靶向性肝癌腺病毒基因治疗奠定基础.
- [1]姜晓兵,赵洪洋,周凤,等.RNA干扰真核表达载体pEGFP-H1介导的血管内皮生长因子shRNA治疗人胶质瘤的实验研究[J].2005,(8).
- [2]汤绍辉,杨冬华,舒建昌,等.人胰岛素样生长因子Ⅱ基因P1、P3 启动子克隆及意义[J].2003,(12).
- [3]魏道严,戴冰冰,陈诗书.放射诱导经Egr-1启动子调控的腺病毒介导CDglyTK基因的肿瘤靶向表达[J].2001,(16).
- [4]G, Vassaux,P, Martin-Duque.Use of suicide genes for cancer gene therapy: study of the different approaches.[J].2004,4(4).
- [5]G, Cao,S, Kuriyama,J, Gao,etc.In vivo gene transfer of a suicide gene under the transcriptional control of the carcinoembryonic antigen promoter results in bone marrow transduction but can avoid bone marrow suppression.[J].1999,15.
- [6]J S, Sussenbach.The gene structure of the insulin-like growth factor family.[J].1989,1(1).
- [7]Cariani E.Expression of insulin-like growth factor II,\u03b1-fetoprotein and hepatitis B virus transcripts in human primary liver cancer[J].1991.
- [8]Dan, Niculescu-Duvaz,Ion, Niculescu-Duvaz,Caroline J, Springer.Design of prodrugs for suicide gene therapy.[J].2004,90.